论文部分内容阅读
目的探讨单克隆抗体MG7对卵巢恶性肿瘤的诊断价值及对患者预后的影响。方法应用免疫放射分析法和免疫荧光流式细胞技术同时检测 46例卵巢恶性肿瘤患者血清和组织中MG7 Ag水平 ,并进行了随访。结果①单克隆抗体MG7诊断卵巢癌的敏感性血清学方法为 5 2 .2 % ,组织学方法为 6 3.0 % ,二者之间无显著性差异 (P >0 .0 5 )。②MG7血清值和FI值呈明显正相关 (r =0 .395 ,t =2 .85 2 ,P <0 .0 5 )。③血清MG7阳性组 3年生存率显著低于MG7阴性组 (P <0 .0 5 )。结论单克隆抗体MG7对卵巢恶性肿瘤具有一定的诊断价值 ,血清MG7水平测定可作为判断卵巢癌患者预后的一个参考指标。
Objective To investigate the diagnostic value of monoclonal antibody MG7 in ovarian cancer and its prognosis. Methods The serum and tissue levels of MG7 Ag in 46 patients with ovarian cancer were detected by immunoradiometric assay and immunofluorescence flow cytometry at the same time. Results ① The serological method of monoclonal antibody MG7 for the diagnosis of ovarian cancer was 52.2% and the histological method was 6 3.0%. There was no significant difference between the two (P> 0.05). (2) There was a significant positive correlation between MG7 serum level and FI (r = 0.395, t = 2.852, P <0.05). ③ The 3-year survival rate of serum MG7-positive group was significantly lower than that of MG7-negative group (P <0.05). Conclusion The monoclonal antibody MG7 has certain diagnostic value in malignant ovarian tumors. Serum MG7 level can be used as a reference index to judge the prognosis of patients with ovarian cancer.